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ABSTRACT
Objective: To determine whether the association between multiple sclerosis (MS) and Leber hered-
itary optic neuropathy (LHON) (known as “Harding disease”) is a chance finding, or the 2 disorders are
mechanistically linked.
Methods: We performed a United Kingdom–wide prospective cohort study of prevalent cases of
MS with LHON mitochondrial DNA (mtDNA) mutations. The new cases were compared with
published cases, enabling a comprehensive clinical description. We also performed a meta-analysis
of studies screening patients with MS for LHON mtDNA mutations to find evidence of a genetic
association.
Results: Twelve new patients were identified from 11 pedigrees, and 44 cases were identified in
the literature. The combined cohort had the following characteristics: multiple episodes of visual
loss, predominance for women, and lengthy time interval before the fellow eye is affected
(average 1.66 years), which is very atypical of LHON; conversely, most patients presented without
eye pain and had a poor visual prognosis, which is unusual for optic neuritis associated withMS. The
number of UK cases of LHON-MS fell well within the range predicted by the chance occurrence of
MS and the mtDNA mutations known to cause LHON. There was no association between LHON
mtDNA mutations and MS in a meta-analysis of the published data.
Conclusions: Although the co-occurrence of MS and LHONmtDNAmutations is likely to be due to
chance, the resulting disorder has a distinct phenotype, implicating a mechanistic interaction.
Patients with LHON-MS have a more aggressive course, and prognostication and treatment
should be guarded. Neurology® 2013;81:2073–2081
GLOSSARY
BNSU 5 British Neurological Surveillance Unit; LHON 5 Leber hereditary optic neuropathy;MS 5 multiple sclerosis; mtDNA 5
mitochondrial DNA; PPMS 5 primary progressive multiple sclerosis; RRMS 5 relapsing-remitting multiple sclerosis.
Leber hereditary optic neuropathy (LHON) is a maternally inherited form of blindness character-
ized by the preferential loss of the retinal ganglion cells and subsequent optic nerve degeneration.
The visual prognosis is poor, and the majority of patients remain registered legally blind for the
rest of their lives with a substantial impact on their quality of life.1
Shortly after the identification of mitochondrial DNA (mtDNA) mutations causing LHON,
case series described the m.11778A.G mtDNA mutation in patients with features of both
LHON and multiple sclerosis (MS).2 These patients were all women, and 6 were considered to
have clinically definite MS, while the other 2 had visual loss with white matter abnormalities
on MRI suggestive of demyelination. Further reports and case series were published of
MS associated with all 3 primary LHON mutations (m.11778A.G, m.3460A.G, and
m.14484T.C),3,4 and this particular disease association became known as “Harding disease”
(here termed LHON-MS).
Given that LHON is a rare disorder, affecting approximately 1 in 30,000 to 50,000 in England
and other northern European populations,527 the growing number of patients described with
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LHON-MS has been considered to be greater
than expected by chance.8 This led to specula-
tion of an interaction between the mitochon-
drial dysfunction in LHON and the emerging
immunologic mechanism in MS.
To resolve this issue, we conducted the first
prospective study of patients with LHON
mutations and an MS-like illness (LHON-MS
cases) and compared these findings with cases
systematically ascertained from the published
literature. The published cases were identified
from both clinical case reports and case series,
and molecular genetic screening of MS cohorts.
Our aims were to 1) define the clinical pheno-
type in a large cohort of patients with an over-
lapping LHON-MS phenotype, 2) compare
this phenotype with “classic” LHON and MS,
and 3) understand potential underlying disease
mechanisms, particularly whether the associa-
tion occurs purely by chance.
METHODS Survey of prevalent cases. Prevalent cases in the
United Kingdom were identified through the British Neurological
Surveillance Unit (BNSU) coordinated by the Association of British
Neurologists. Between 2005 and 2010, the BNSU contacted more
than 600 Association of British Neurologists members every month,
requesting details of new or existing suspected cases of LHON and
MS.Members notifying the BNSUwere contacted by the study team
to obtain consent and collect 1) clinical data describing the sex, age at
onset, and clinical course, and 2) the results of relevant investigations.
These included brain MRI; CSF cell count, protein content, and oli-
goclonal band analysis; evoked potential results analysis; and mtDNA
analysis. Cases were included if they met current diagnostic criteria for
MS9 and harbored an mtDNA mutation known to cause LHON, or
harbored a LHON mutation and had clinical investigations compat-
ible with MS.9 Patients were considered to qualify as being registered
blind if their best-corrected visual acuity was 3/60 (Snellen) or worse.10
Systematic review of published cases of LHON and an
MS-like illness. A systematic review of the medical literature, with
no date limits, for articles written in English or French was con-
ducted using the following search terms in MEDLINE on May
28, 2013: (leber or leber’s or lhon or mitochondrial disease) and
(MS or transverse myelitis or neuromyelitis optica or devic or devic’s
or nmo or white matter lesions or demyelination or harding or
harding’s). The search was conducted independently by 2 of the
authors (G.P. and A.B.). Data collection was conducted indepen-
dently by 2 of the authors (G.P. and A.B.) and in the case of any
disagreement, the relevant articles were re-reviewed to reach a con-
sensus. We defined cases of LHON-MS as those with a primary
LHON mutation and a clinical description compatible with MS
with appropriate diagnostic test results, or patients described as hav-
ing “clinically definite” MS based on contemporaneous diagnostic
criteria. Patients not meeting these criteria were excluded. Data
extracted included mutation status, sex, age at onset, first symptom
(visual or neurologic), type of visual loss (unilateral, sequential, or
bilateral simultaneous), interval before involvement of fellow eye,
number of episodes of visual loss, response to corticosteroids, pres-
ence of ocular pain, subtype ofMS (relapsing-remittingMS [RRMS]
or primary progressive MS [PPMS]), and presence of oligoclonal
bands and diagnostic MRI findings. When indicated, study authors
were contacted to provide additional clinical information.
Meta-analysis of mtDNA studies in MS. A systematic review
of the medical literature written in English or French with no date
limits was conducted using the following search terms in OvidSP
MEDLINE onMay 20, 2013: (multiple sclerosis and [mitochon-
drial dna or mtdna] and mutation). We restricted our analysis to
known pathogenic mutations of mtDNA detected using either
allele-specific assays or mtDNA sequencing. We excluded reports
describing associations with common polymorphic mtDNA
alleles (.1% minor allele frequency) or mtDNA haplogroups.
Data collected included the number of positive MS patients for
each of the 3 primary LHON mutations, the number of MS
patients and controls screened, the entry criteria of the MS
patients, and race/ethnicity of participants.
Standard protocol approvals, registrations, and patient
consents. Institutional research ethics board approval was obtained,
and written informed consent was secured from all patients partici-
pating in the study.
RESULTS Survey of prevalent cases.The BNSU received
27 notifications of cases not previously reported, of
whom 12 originating from 11 pedigrees met our criteria
for LHON-MS (table 1). One case (patient 9) who had
MSwithout visual symptoms or signs was identified with
the m.11778G.A mutation. All other patients had a
clinical picture of MS with severe involvement of the
anterior visual pathway. Fifteen patients were excluded:
i) 10 patients in whom we were not able to substantiate
the molecular genetic diagnosis, ii) 3 patients who did
not meet criteria for MS, and iii) 2 patients for whom no
further clinical data were obtainable.
Of the 12 patients identified in this BNSU survey,
9 harbored the m.11778A.G mutation, 2 the
m.3460A.G mutation, and 1 the m.14484A.G
mutation. Eleven of the patients were women. All
presented in early to mid adulthood (average age
25.6 years, range 18–37 years), with clinical and para-
clinical evidence of MS (table 1). Nine of 12 patients
had RRMS, and in 3 the course was PPMS.
Of the 11 patients having visual loss, 6 had visual
acuity meeting criteria for blindness registration. Four
of the patients had ocular pain at the onset of visual
symptoms. One patient had bilateral visual loss at pre-
sentation, and the other 9 had sequential visual loss with
intervals of up to 17 years before both eyes were affected
(the interval was more than 1 year in 7 patients). Five of
the patients had more than 2 episodes of visual loss over
their disease course. Four of the patients had some degree
of visual recovery after the onset of symptoms, and
patient 4 experienced slight initial improvement with
corticosteroid therapy. A representative MRI from
patient 8 is shown in figure 1, with fundal images
and optical coherence tomography (figure 2).
Systematic review of published cases. The search strat-
egy identified 122 articles. After reading the abstracts,
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Table 1 Case series of 12 new patients with LHON-MS
Patient
no. Mutation Sex
Onset
age, y Family history of MS Family history of LHON
Visual onset (interval between
eyes)
Visual
recovery
Ocular
pain
1 11778 F 30 Mother with MS Brother with LHON Sequential visual loss (weeks) 2 NA
2 11778 F 37 Sequential visual loss (5 y) 2 1
3 11778 F 35 Sequential visual loss (3 mo) 2 2
4 11778 M 27 Sister with MS and blindness
(mutation status unknown);
similar history in maternal
grandmother
Sequential visual loss (months) 1 NA
5 11778 F 33 Sister with MS and 11778 mutation Sequential visual loss (15 mo) 2 2
6 11778 F 27 Sequential visual loss (6 y) 1 2
7 11778 F 18 Brother with LHON Sequential visual loss (5 y) 2 NA
8 11778 F 27 Multiple family members
with LHON
Sequential visual loss (17 y) 1 1
9 11778 F 27 No visual loss
10 3460 F 25 Mother of patient 11 Sequential visual loss (2 y) NA 1
11 3460 F 20 Daughter of patient 10 Bilateral simultaneous visual loss 2 NA
12 14484 F 25 Sequential visual loss (8 y) 1 1
Patient
no.
Total
no.
visual
events
Steroid
response
to visual
events
Retinal
exam
Visual
outcome
MS
phenotype MS symptoms/signs
First symptom
visual or other
neurologic?
(interval)
Oligoclonal
bands MRI
1 2 NA OA LP OU RRMS Episodic weakness/sensory loss; urinary
dysfunction; hemicord syndrome; extensor
plantar responses
Visual (1 y) 2 Multiple juxtacortical
and WM lesions
2 2 NA OA CF OS;
LP OD
RRMS Visual episodes with a single sensory/motor
event
Visual (1 y) NA Multiple WM lesions c/w
demyelination
3 2 NA LB PPMS Dysarthria, tremor, truncal instability;
tetraparesis/ataxia (w/c bound)
Visual (1 y) 2 Multiple supra- and
subtentorial WM lesions
4 3 1 (first
event
only)
OA LP OU PPMS Progressive weakness/ataxia; internuclear
ophthalmoparesis; urinary symptoms; spasticity
and extensor plantar responses
Progressive gait
disturbance (8 y)
1 Multiple supra- and
subtentorial WM lesions
5 NA 2 CF OU RRMS 2 sensory relapses and 1 motor relapse Visual (4 y) NA Multiple supra- and
subtentorial WM lesions,
evolution between
scans
6 .3 NA 1/9 OS;
HM OD
PPMS Progressive ataxia, spasticity, sensory loss,
predominantly LE
Visual (17 y) 1 Multiple WM lesions c/w
demyelination;
incidental aneurysm
ACA 7.7 mm
7 2 NA OA HM OS;
1/60 OD
RRMS Episodes sensory loss, ataxia, weakness,
dysarthria; urinary retention and fatigue
Visual (4 y) 1 Multiple WM lesions c/w
demyelination
8 3 2 NA 6/60
OS; 2/
24 OD
RRMS Sensory episodes, Lhermitte symptom Sensory loss (3 y) NA Subcortical WM and
cervical spinal cord
lesions
9 0 RRMS Episodes sensory loss, ataxia, weakness; LE
spasticity; 2ry progressive course after 4 y
Neurologic only NA Subcortical WM and
cervical spinal cord
lesions
10 4 NA NA RRMS Multiple sensory relapses, episode of transverse
myelitis
Visual (2 y) 2 Subcortical WM and
spinal cord lesions
11 1 NA 1/40
OS; 2/
30 OD
RRMS 2 episodes weakness/sensory loss, Lhermitte
symptom
Visual (6 mo) NA Subcortical WM and
spinal cord lesions
12 4 NA LB RRMS Episodes of limb and hemibody sensory loss,
episodes hemianopia with corresponding WM
lesions; LE spasticity and extensor plantar
responses
Visual (7 y) 1 Multiple supra- and
subtentorial WM lesions
Abbreviations: ACA5 anterior cerebral artery; CF5 count fingers; c/w 5 compatible with; HM 5 hand movements; LB5 legally blind; LE5 lower extremity;
LHON 5 Leber hereditary optic neuropathy; LP 5 light perception; MS 5 multiple sclerosis; NA 5 not available; OA 5 optic atrophy; OD 5 right eye;
OS 5 left eye; OU 5 both eyes; PPMS 5 primary progressive MS; RRMS 5 relapsing-emitting MS; 2ry 5 secondary; w/c 5 wheelchair; WM 5 white matter.
1 5 clinical feature present; 2 5 absent.
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39 titles were selected for review of the full-text ar-
ticles. The bibliography of these articles revealed 8
additional publications, which were also included in
the final review. From these 47 articles, we identified
44 patients who met our criteria for inclusion. These
patients and their clinical details, with references, are
summarized in table e-1 on the Neurology® Web site
at www.neurology.org. Eleven patients were excluded
from the analysis on the basis that they did not have
sufficient evidence for the diagnosis of MS, despite
the presence of LHON mutations and paraclinical
investigations suggestive of MS (table e-2). We
excluded 29 patients who had been reported from
13 publications, and have provided descriptions and
reasons for exclusion in table e-3 (the most common
reason for exclusion, in 22 cases, was the absence of a
documented primary LHON mutation).
There were no statistically significant differences
between the 12 new cases and the 44 patients identi-
fied from the published literature; therefore, we com-
bined the 2 datasets in order to summarize the salient
features of all 56 patients. We present various metrics
in aggregate in table 2. Most patients presented from
early to mid adulthood with a predominance of affected
women (2.1:1). Most had RRMS, the m.11778 G.A
mutation, and a poor visual prognosis. Many of the
patients had features atypical for LHON, such as the
presence of ocular pain at presentation (47.6%), a
lengthy time interval before involvement of the fellow
eye (average of 1.66 years, and up to 17 years in one
case), and more than 2 episodes of visual loss (25%).
Meta-analysis of mtDNA studies in MS. The search
strategy identified 59 articles, 18 of which were rele-
vant and thus included in this study. Reference
searching of these 18 articles yielded 4 further articles
for inclusion. We summarize the results from these
22 articles reporting the frequency of pathogenic
mtDNA mutations in MS cases in table 3. Of the
1,666 patients with MS screened, 5 patients with
primary LHON mutations were identified (these
patients are also individually described in table e-1).
All 5 patients with mutations had severe and early
optic nerve involvement (a subgroup containing only
209 patients from 5 studies,3,8,11213 although the lack
of control groups in most of these studies makes this
finding difficult to evaluate). No LHON mutations
were identified from 1,436 matched controls,
although this was not statistically different from the
mutation rate in the patients with MS (p 5 0.066).
The mutation rate in the patients with MS from this
meta-analysis was not statistically different compared
with the prevalence rates for the primary LHON
mutations (homoplasmic or heteroplasmic) previ-
ously reported in the population.14
DISCUSSION Here, we describe 12 LHONmtDNA
mutation carriers with clinically definite MS prospec-
tively ascertained from the BNSU survey, and 44
additional cases from the published literature. Within
this group, there was a broad range of features, from
typical RRMS without visual involvement, to patients
with severe ocular involvement and varying degrees of
neurologic disability attributable to MS. On the
whole, most patients had severe visual impairment
(so severe as to be registered legally blind in 50%)
and the phenotype of RRMS predominated, being
present in 70.2%. Despite the limitations of our
study, which include the selection bias of cases
referred to neurologists engaged with the BNSU,
the inherent publication bias of case reports, and
the language limitations of our literature review, we
observed a remarkably consistent phenotype between
our study group and the previously reported cases.
How do the reported patients with LHON-MS
differ from classic LHON, and typical MS? Compared
with classic LHON, the age at onset and bilateral
sequential visual involvement were typical, as was the
lack of visual recovery. The distribution of 3 primary
mtDNA LHON mutations also fell within the range
previously reported in population-based epidemiologic
studies.527 However, these patients with LHON-MS
differ significantly from the standard population in
LHON regarding the predominance of affected
women (2.1:1), the large proportion of patients with
more than 2 visual events (25%) or persisting unilateral
visual loss (8.5%), and the long time interval before
both eyes became affected (average 1.66 years, and up
to 17 years). These would be extremely unusual for
LHON in which typically the sex ratio favors men by a
ratio of 4:1, patients have only 2 visual events, and
both eyes are almost invariably affected within 6months
Figure 1 Head and cervical spine MRI findings in patient 8
(A) Transverse axial T2 fluid-attenuated inversion recovery image of the head demonstrates
multiple ovoid high-signal lesions in the periventricular white matter and juxtacortically.
(B) Sagittal T2 image reveals lesionswith an orientation resemblingDawson fingers. (C) Sagittal
T2 image of the cervical spine demonstratesmultiple high-signal lesions that are each less than
one spinal segment. Taken together, these findings meet MRI diagnostic criteria for multiple
sclerosis.
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Figure 2 Visual examination and optical coherence tomography findings in patient 8
(A) Bilateral optic atrophy is demonstrated on fundoscopic examination (RE 5 right eye, LE 5 left eye). (B) Optical coherence tomography (OCT) measure-
ments were obtained with the high-resolution spectral-domain Cirrus platform (Carl Zeiss Meditec, Dublin, CA). The average retinal nerve fiber layer (RNFL)
thickness was 70 mm in the right eye (OD) and 66 mm in the left eye (OS). (C) The analysis software automatically selects the appropriate normative range for
the patient, and the peripapillary RNFL measurements (dark traces) are represented within color-coded distribution centiles: i) red ,1%, ii) yellow 1%–5%,
and iii) green 5%–95%. The OCT measurements confirm significant RNFL thinning in keeping with the optic disc pallor. TSNIT 5 temporal-superior-nasal-
inferior-temporal.
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(at most 1 year).15 This case series demonstrates
that slightly more than half of all LHON-MS cases
present with an atypical phenotype for LHON,
based on the above uncharacteristic features for
classic LHON (table 2).
When comparing LHON-MS with MS, shared
features are age at onset, predilection for women, and
predominance of the RRMS phenotype (71.1%).
However, important differences fromMS in our study
are the high proportion of patients with visual involve-
ment (96%), lack of ocular pain in most patients (only
10 patients reported ocular pain), absence of visual
recovery in most patients (72.1%), and visual outcome
resulting in registrable blindness in 50%. This is signif-
icantly more prevalent and severe than in typical MS,
whereby 50% of patients withMS are expected to have
visual involvement through the entire course of their
illness and, of these, 85% to 95% recover to visual acu-
ity better than 6/9.16 Furthermore, optic neuritis is
ordinarily accompanied by ocular pain in more than
90% of patients.17 LHON-MS does, therefore, appear
to have a clinical phenotype distinct from both LHON
and MS, implying a mechanistic interaction between
the 2 disorders.
In the United Kingdom, LHON mtDNA muta-
tions are found in 1/300 of the population (1/1,000
of the population in homoplasmic state),14 and MS
affects 2.6/1,000.18 This suggests that approximately
1 in 115,000 of the UK population will harbor both a
LHON mutation and develop MS by chance. How-
ever, if we assume that only homoplasmic LHON
mutations are associated with disease, then homoplas-
mic LHON mutations overlap with MS in approxi-
mately 1 in 400,000 of the UK population. Based on
the current population of approximately 63 million
from the 2011 census, this equates to 150 individuals,
which is far greater than the number ascertained
through our national survey. The cases we have iden-
tified could therefore represent the chance finding of
relatively common mtDNA mutations and a rela-
tively common neuroinflammatory disorder. Based
on these observations, it would be unwise to conclude
that LHON mtDNA mutations predispose to MS.
This is supported by several negative studies screening
MS cohorts for LHON mtDNA mutations (table 3).
How can we reconcile this conclusion with the
distinct phenotype of LHON-MS? There are several
possibilities: 1) that the mtDNA mutations modify
the phenotype of MS, causing “atypical optic neuri-
tis,” which is painless, severe, and irreversible; 2) that
the genetic and environmental factors that predispose
to MS, enriched in women, precipitate acute LHON
in mtDNA mutation carriers who would otherwise
have remained asymptomatic; or 3) a combination of
the above. In other words, that having the LHON
mtDNA mutation would direct a coincidental inflam-
matory response to affect the vulnerable anterior visual
pathway in individuals already susceptible to develop
MS. In this case, there would be interdependence,
and an interplay causing this unusual phenotype. A
similar scenario may also exist in patients with the
Table 2 Summary of clinical characteristics of all reported cases of LHON-MS
Total patients (pedigrees) 56 (53)
Average age at onset, y (SD; range) 30.5 (10.5; 17–68)
F:M ratio 19:9 (2.1)
RRMS, % (n) 70.2 (33/47)
11778 mutation, % (n) 80.4 (45/56)
3460 mutation, % (n) 10.7 (6/56)
14484 mutation, % (n) 8.9 (5/56)
CSF oligoclonal bands present, % (n) 67.6 (25/37)
MRI with MS-compatible abnormalities, % (n) 100 (51/51)
Vision in best eye £3/60, % (n) 50.0 (25/50)
Ocular pain at presentation, % (n) 47.6 (10/21)
No visual recovery after onset, % (n) 72.1 (31/43)
Clinical presentation of visual loss (n 5 47)
SVL, % (n) 72.3 (34/47)
Time interval between eyes in patients with SVL,a y (SD; range) 1.66 (2.10; 0.04–17)
Bilateral simultaneous visual loss, % (n) 14.9 (7/47)
Unilateral visual loss only, % (n) 8.5 (4/47)
No visual loss, % (n) 4.3 (2/47)
Total no. of visual eventsb (n 5 44), % (n)
0 4.5 (2/44)
1 9.1 (4/44)
2 61.4 (27/44)
‡3 25.0 (11/44)
Initial clinical presentation (n 5 46)
Initial presentation with visual symptoms, % (n) 73.9 (34/46)
Interval to development of MS symptoms, y (SD; range) 3.9 (4.4; months to 20 y)
Initial presentation with MS symptoms, % (n) 26.1 (12/46)
Interval to development of visual symptoms, y (SD; range) 7.3 (6.9; 0.8–10)
LHON phenotypec (n 5 43), % (n)
Atypical 51.2 (22/43)
Typical 48.8 (21/43)
Abbreviations: LHON 5 Leber hereditary optic neuropathy; MS 5 multiple sclerosis;
RRMS 5 relapsing-remitting MS; SVL 5 sequential visual loss.
Denominators vary for different metrics because information was not available from all
patients for each measured characteristic.
aMeasures the time before both eyes became affected in patients who had SVL (i.e., this
metric does not include patients with bilateral simultaneous visual loss, unilateral visual
loss, or no visual loss).
bDefined as the patient-reported episodes of visual deterioration, and for these purposes
“bilateral simultaneous visual loss” is considered to be a single visual event.
c “Typical” LHON phenotype was defined as patients with SVL with an interval of ,1 year,
with 2 visual episodes only, and limited visual recovery; phenotypes that diverged from this
definition were considered to be “atypical.” (Patients with a single episode of “bilateral visual
loss” and no further visual episodes were not counted for this metric because this clinical
situation can occur when SVL is unnoticed until the second eye is affected. LHON mutation
carriers without visual loss were similarly not included in this metric.)
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mitochondrial optic neuropathy due to OPA1 muta-
tions, whereby patients have been described with coin-
cident MS.19 Understanding the mechanism of this
interaction is likely to provide novel insights into the
pathophysiology of both disorders.
LHONmtDNAmutations cause a defect of respi-
ratory chain complex I,20 and given the recent obser-
vation of reduced respiratory chain activity in both
acute and chronic MS lesions,21,22 it is conceivable
that the 2 disorders interact at the biochemical level,
through a defect of ATP (adenosine triphosphate)
synthesis. However, LHON mtDNA mutations also
sensitize cells to apoptotic cell death, perhaps exposing
neurons to the downstream consequences of an inflam-
matory insult. There is also evidence that mtDNA co-
des for a maternally inherited human leukocyte
antigen,23 and that mtDNA itself can be proinflamma-
tory if released into the circulation. It is therefore pos-
sible that the underlying sequence variations themselves
modify the inflammatory response. Intriguingly, 2 of
the new cases we report are related (mother and
daughter), and 5 of the published cases described
additional affected family members with MS. This
raises the possibility of an inherited predisposition
to LHON-MS, but it is difficult at this stage to know
whether this simply reflects the coinheritance of the
LHON mtDNA mutation on a high-risk nuclear
genetic background, or whether additional factors
come in to play, such as the background mtDNA
haplogroup.
With this in mind, how should we treat patients
with LHON-MS? There is evidence suggesting that
Table 3 Summary of all studies screening patients with MS for primary LHON mtDNA mutations
Study Year
No. of MS
patients
11778
mutation
14484
mutation
3460
mutation
No. of
controls Comment
Ethnicity/
nationality
3 1994 307 0 0 0 129 Unselected MS patients British
3 1994 20 1 0 2 0 MS patients with severe/early optic nerve involvement British
31 1994 36 0 0 0 48 Unselected adult MS patients German
31 1994 30 0 0 0 0 Unselected pediatric MS patients German
32 1995 80 0 NA NA 0 Unselected MS patients (18 had bilateral optic neuropathy);
no screening for 14484 or 3460 mutations
Japanese
33 1995 53 0 0 0 0 Unselected MS patients American
34 1995 30 0 0 0 18 18 optic neuritis patients (11 of whom developed MS) and
12 unselected MS patients
Italian
11 1995 53 1 0 0 “Several
hundred”
MS patients with severe/early optic nerve involvement Italian
35 1996 100 0 0 0 100 Unselected MS patients German
36 1996 9 0 0 0 0 Hereditary MS compatible with maternal inheritance British
37 1996 3 0 0 0 0 Unselected MS patients American
12 1997 22 0 0 0 0 MS patients with severe/early optic nerve involvement American
13 1997 74 1 0 0 99 MS patients with severe/early optic nerve involvement Italian
38 1998 13 0 0 0 20 Unselected pediatric MS patients German
39 1998 6 0 0 0 0 Pediatric MS with severe/early optic nerve involvement German
40 1999 77 0 0 0 84 Unselected MS patients (Caucasian) Caucasian/
American
e-1 1999a 42 0 0 0 0 Clinically definite familial MS American
e-2 1999b 103 0 NA 0 0 Unselected MS patients American
e-3 2000 101 0 0 0 90 Unselected MS patients Italian
8 2000 40 0 0 0 0 MS patients with severe/early optic nerve involvement Belgian
e-4 2001 20 0 0 0 0 Unselected MS patients; only 15 tested for 14484 and
12 tested for 3460 mutations
Korean
e-5 2001 75 0 0 0 75 Unselected MS patients French
e-6 2008 159 0 0 0 607 Unselected MS patients Caucasian/
British
e-7 2011 213 0 0 0 166 Pediatric acute demyelinating syndrome cases Canadian, mixed
ethnicity
Total 1,666 3 0 2 1,436 Note: no mutations found in any control subjects
Abbreviations: LHON 5 Leber hereditary optic neuropathy; MS 5 multiple sclerosis; mtDNA 5 mitochondrial DNA; NA 5 not available.
References e-1 through e-7 are available on the Neurology® Web site at www.neurology.org.
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idebenone may limit progression in patients with
LHON who have discordant visual acuity and are pre-
sumably early in their disease course.24 There is also
lengthy experience with disease-modifying agents in
MS, although these have not been shown to have any
effect on long-term disability progression.25 Based on
our own experience, this is a difficult and emotive issue,
and the data are insufficient to offer clear guidance at
present. Having said that, idebenone is safe in LHON,
could prevent visual disability, and it led to visual
improvement in one26 of two reported case reports with
LHON-MS.26,27 Others reported the use of mitoxan-
trone,27,28 with improvement in one patient.28 Mitox-
antrone is considered to be a therapeutic option in
severe MS for selected patients, but its use is difficult
to justify because of its severe short- and long-term
adverse reactions in the context of safer alternatives.29
In any event, the presence of an LHON mutation in a
patient with MS indicates a high likelihood of severe
visual disability, and therefore early disease-modifying
therapy to prevent relapses may be preferable despite
the uncertainty relating to long-term benefits. Further-
more, a recent study indicates that a portion of patients
withMS have improvements in visual evoked potentials
on treatment with 4-aminopyridine,30 and this LHON-
MS patient group with severe visual prognosis may be a
suitable subpopulation of MS for study with this agent.
In the absence of any evidence in this situation,
treatment should be determined on a case-by-case basis
in a center with expertise in the management of MS.
There is a clear need to evaluate these different treat-
ment approaches in a prospective, objective way. This
will be extremely challenging, given the difficulty of
studying treatment effects in rare diseases, and the size
of the studies needed to demonstrate a treatment effect
in MS. Identifying a reliable, clinically relevant bio-
marker would provide a valuable tool in developing
new treatments for LHON-MS, enabling open-labeled
studies as a starting point for this devastating disease.
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